MedAvail (MDVLQ) 10-Q 14 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	14-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	MYOS Corp
Entity Central Index Key	1402479
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		3,112,300

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash	$590	$1,567
Accounts receivable, net	682	982
Inventories, net	1,810	1,814
Prepaid expenses and other current assets	801	745
Total current assets	3,883	5,108
Fixed assets, net	308	313
Intangible assets, net	1,938	1,990
Total assets	6,129	7,411
Current liabilities:
Accounts payable	177	79
Accrued expenses	350	495
Total current liabilities	527	574
Contract liability	108	101
Total liabilities	635	675
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.001 par value; 500,000 shares authorized; no shares issued and outstanding
Common stock, $.001 par value; 8,000,000 shares authorized; 3,102,300 and 3,103,300 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	3	3
Additional paid-in capital	25,387	25,100
Accumulated deficit	-19,896	-18,367
Total stockholders' equity	5,494	6,736
Total liabilities and stockholders' equity	$6,129	$7,411

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Balance Sheets [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	8,000,000	8,000,000
Common stock, shares issued	3,102,300	3,103,300
Common stock, shares outstanding	3,102,300	3,103,300

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statements of Operations [Abstract]
Net sales	$6	$1,546
Cost of sales (excludes amortization of acquired intangibles)	5	405
Gross profit	1	1,141
Operating expenses
Research and development	189	434
Selling, general and administrative	1,288	1,130
Amortization	52
Total operating expenses	1,529	1,564
Operating loss	-1,528	-423
Other income (expense)
Interest income		1
Total other income (expense)		1
Loss before income taxes	-1,528	-422
Income tax expense - current	-1
Net loss and comprehensive loss	($1,529)	($422)
Net loss per share attributable to common shareholders:
Basic and diluted	($0.50)	($0.16)
Weighted average number of common shares outstanding:
Basic and diluted	3,084	2,703

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flow (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash Flows From Operating Activities:
Net loss	($1,529)	($422)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	12	12
Amortization	52
Accretion of contract liability	7
Stock-based compensation	287	303
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	300	-850
(Increase) decrease in inventories	4	-718
(Increase) decrease in prepaid expenses and other current assets	-56	-104
Increase (decrease) in accounts payable and accrued expenses	-54	583
Net cash used in operating activities	-977	-1,196
Cash Flows From Investing Activities:
Additions to fixed assets		-4
Net cash used in investing activities		-4
Cash Flows From Financing Activities:
Proceeds from private placement of common stock		4,735
Offering costs		-72
Net cash provided by financing activities		4,663
Net increase (decrease) in cash	-977	3,463
Cash at beginning of period	1,567	451
Cash at end of period	590	3,914
Supplemental schedule of cash flow information:
Total cash paid for income taxes	1
Supplemental schedule of non-cash investing and financing activities:
Accrued capital expenditures	$7

Nature_of_Operations_Basis_of_

Nature of Operations, Basis of Presentation and Liquidity	3 Months Ended
	Mar. 31, 2015
Nature of Operations, Basis of Presentation and Liquidity [Abstract]
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY	NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY
	Nature of Operations
	MYOS Corporation is an emerging bionutrition and biotherapeutics company focused on the discovery, development and commercialization of products that improve muscle health and function. The Company was incorporated under the laws of the State of Nevada on April 11, 2007. As used in this report, the terms the “Company”, “MYOS”, “our”, or “we”, refer to MYOS Corporation, its predecessor, Atlas Therapeutics Corporation, and subsidiary, unless the context indicates otherwise. On February 25, 2011, the Company entered into an agreement to acquire the intellectual property for Fortetropin®, our proprietary active ingredient from Peak Wellness, Inc. (the "Acquisition"). Since the Acquisition, the Company’s principal business activities have been focused on deepening our scientific understanding of the activity of Fortetropin and to leverage this knowledge to strengthen and build our intellectual property; developing sales and marketing strategies aimed at expanding our commercial presence in the sports nutrition and age management markets; evaluating the value of Fortetropin in therapeutic markets, including the treatment of sarcopenia, cachexia, anorexia, obesity and muscular-related conditions; and, conducting research and development focused on the discovery, development and commercialization of other products and technologies aimed at maintaining or improving the health and performance of muscle tissue. Since its inception in April 2007, the Company has recognized revenues of approximately $7.7 million. The Company’s activities are subject to significant risks and uncertainties.
	Our commercial focus is to leverage our clinical data to develop proprietary products including direct-to-consumer branded products using multiple product delivery formats to target the large, but currently underserved, markets focused on muscle health. Our first commercial product, MYO-T12, is sold in the sports nutrition market under the brand name MYO-X® through a distribution arrangement with Maximum Human Performance (“MHP”). For additional information regarding MHP please refer to Part II, “Item 1. Legal Proceedings.” In February 2014, we expanded our commercial operations into the age management market through a distribution agreement with Cenegenics Product and Lab Services, LLC (“Cenegenics”), under which Cenegenics distributes and promotes a proprietary formulation containing Fortetropin through its age management centers and its community of physicians. While we may continue to sell our products through these and other distributors, we have recently launched Rē Muscle HealthTM, our own direct-to-consumer portfolio of products designed to meet the growing population of individuals focused on proactively addressing health and wellness concerns. Rē Muscle Health, which is available online at www.remusclehealth.com, features a full line of muscle health bars, meal replacement shakes and daily supplement powders each powered by a full 6.6 gram single serving dose of Fortetropin. We believe increased awareness of muscle health and the potential therapeutic benefits of myostatin inhibition will provide a catalyst for the growth of our products. We continue to pursue additional markets such as medical foods and international opportunities. We intend to conduct additional clinical studies and medical research to develop product improvements and new products in consumer preferred dosage forms, to support differentiated and advantaged marketing claims for our products, to enhance our intellectual property and to establish a scientific foundation for therapeutic applications for our technology.
	Basis of Presentation
	The accompanying condensed consolidated balance sheet as of December 31, 2014, which has been derived from audited financial statements, and the unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and disclosures required by U.S. GAAP for complete consolidated financial statements have been condensed or omitted herein. The interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Form 10-K for the year ended December 31, 2014. The unaudited interim condensed consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The Company is responsible for the unaudited interim condensed consolidated financial statements included in this report. The results of operations of any interim period are not necessarily indicative of the results for the full year.
	Liquidity
	As of March 31, 2015, the Company had cash of $590 to meet current obligations and working capital of $3,356 (current assets of $3,883, less current liabilities of $527). We have incurred net losses since our inception. For the three months ended March 31, 2015 and 2014 our net loss was $1,529 and $422, respectively. In addition, net cash used in operating activities for the three months ended March 31, 2015 and 2014 was $977 and $1,196, respectively. At March 31, 2015 and December 31, 2014, we had an accumulated deficit of $19,896 and $18,367, respectively. Since the Company’s inception, net cash provided by financing activities, which has been our primary source of cash flows, was $15,345. At March 31, 2015, we had no outstanding borrowings under our revolving credit agreement (the “Revolving Note”). For additional information about the Revolving Note refer to “NOTE 6 – Debt.” As of the filing date of this Form 10-Q, management believes that there is not sufficient capital resources from operations and existing financing arrangements in order to meet operating expenses and working capital requirements for the next twelve months. We expect that we will need to seek additional funding through public or private financing or through collaborative arrangements with strategic partners in the third quarter of 2015 as we do not expect to have sufficient cash to operate past such date. These facts raise substantial doubt about the Company’s ability to continue as a going concern. Accordingly, we are evaluating various alternatives, including reducing operating expenses, including personnel costs, securing additional financing for future business activities and other strategic alternatives. There can be no assurance that the Company will be able to generate the level of operating revenues in its business plan, or if additional sources of financing will be available on acceptable terms, if at all. If no additional sources of financing are available, our future operating prospects may be adversely affected. No adjustments have been made to these financial statements to reflect this uncertainty.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation
	The accompanying unaudited interim condensed consolidated financial statements include the accounts of MYOS Corporation and its wholly-owned subsidiary, Atlas Acquisition Corp. All material intercompany balances and transactions between and among its consolidated subsidiary have been eliminated.
	Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, equity and the disclosures of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates. Significant items subject to such estimates include but are not limited to the valuation of stock-based awards, revenue recognition, measurement of allowances for doubtful accounts and inventory reserves, the selection of asset useful lives, fair value estimations used to test long-lived assets, including intangibles, impairments and provisions necessary for assets and liabilities.
	The Company has not recorded sales to its distributors during the first quarter 2015 and fourth quarter 2014, and sales to distributors were minimal during the third quarter 2014, accordingly the Company cannot predict what future sales, if any, will come from its distributors. In addition, the Company recently launched its direct-to-consumer branded products. Management’s estimates, including evaluation of impairment of long-lived assets and inventory reserves are based in part on forecasted future results. A variety of factors could cause actual results to differ from forecasted results and these differences could have a significant effect on asset carrying amounts.
	Cash and Cash Equivalents
	As of March 31, 2015 and December 31, 2014, the Company had cash of $590 and $1,567, respectively. The Company considers all highly liquid investments purchased with a maturity of three months or less and money market accounts to be cash equivalents. At March 31, 2015 and December 31, 2014, the Company had no cash equivalents.
	The Company maintains its bank accounts with high credit quality financial institutions and has never experienced any losses related to these bank accounts. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its financial institutions. The balance at times may exceed federally insured limits. At March 31, 2015 and December 31, 2014, the Company's uninsured cash balances totaled $309 and $1,292, respectively.
	Concentrations of Risk, Significant Customers and Significant Supplier
	Management regularly reviews accounts receivable and if necessary, establishes an allowance for doubtful accounts that reflects management’s best estimate of amounts that may not be collectible based on historical collection experience and specific customer information. Bad debt expense recognized as a result of an allowance for doubtful accounts is classified under selling, general and administrative expenses in the statements of operations. Bad debt expense was $0 for the three months ended March 31, 2015 and 2014.
	At March 31, 2015 and December 31, 2014, the Company had the following concentrations of net accounts receivable with customers:
			March 31,			December 31,
	(In thousand $)		2015			2014
	Cenegenics		$	1,072		$	1,372
	Allowance for doubtful accounts			(390	)		(390	)
	Accounts receivable, net		$	682		$	982
	If we are unable to collect our outstanding accounts receivable from Cenegenics, our operating results and financial condition will be adversely affected.
	The Company currently relies on one third-party manufacturer to produce Fortetropin (see NOTE 12 – Commitments and Contingencies - Supply Agreement). This manufacturer purchases all the needed raw materials from suppliers and coordinates any additional production steps with third-parties. We have multiple vendors for blending, packaging and labeling. The Company is pursuing other supply alternatives.
	Inventories, net
	Inventories are valued at the lower of cost or market, with cost determined on a first in, first-out basis. The Company writes down inventories to net realizable value based on forecasted demand, market conditions or other factors.
	Fixed Assets
	Fixed assets are stated at cost and depreciated to their estimated residual value over their estimated useful lives of 3 to 7 years. Leasehold improvements are amortized over the lesser of the asset's useful life or the contractual remaining lease term including expected renewals. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are reversed from the accounts and the resulting gains or losses are included in the statements of operations.
	Depreciation is provided using the straight-line method for all fixed assets.
	We review our fixed assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. If the assets are determined to be unrecoverable, an impairment loss is calculated by determining the difference between the carrying values and the estimated fair value. We did not consider any of our fixed assets to be impaired during the three months ended March 31, 2015 and 2014.
	Intangible Assets
	The Company’s intangible assets consist primarily of intellectual property pertaining to Fortetropin, including its formula, trademarks, trade secrets, patent application and domain names, which was determined to have a fair value of $2,000 as of December 31, 2011. Based on expansion into new markets and introduction of new formulas, management determined that the intellectual property had a finite useful life of ten (10) years and began amortizing the asset over its estimated useful life beginning April 2014. There were no impairment losses recorded during the three months ended March 31, 2015 and 2014.
	In July 2014, the Company acquired the United States patent application for the manufacture of Fortetropin from Deutsches Institut fur Lebensmitteltechnik e.V. - the German Institute for Food Technologies (“DIL”). The cost of the patent application, which was capitalized as an intangible asset, was determined to be $101, based on the present value of the minimum guaranteed royalty payable to DIL using a discount rate of 10%. The intangible asset will be amortized over an estimated useful life of ten (10) years. The remaining contingent royalty payments will be recorded as the contingency is resolved and the royalty becomes payable under the arrangement. For additional information on the amended supply agreement with DIL refer to “NOTE 12 – Commitments and Contingencies - Supply Agreement.”
	Intangible assets also includes patent costs associated with applying for a patent and being issued a patent. Costs to defend a patent and costs to invalidate a competitor’s patent or patent application are expensed as incurred. Upon issuance of the patent, capitalized patent costs are reclassified from intangibles with indefinite lives to intangibles with finite lives and amortized on a straight-line basis over the shorter of the estimated economic life or the initial term of the patent, generally 20 years.
	Intangible assets at March 31, 2015 and December 31, 2014 consisted of the following:
			March 31,			December 31,
	(In thousand $)		2015			2014
	Intangibles with finite lives:
	Intellectual property		$	2,101		$	2,101
	Less: accumulated amortization			(207	)		(155	)
	Total intangibles with finite lives:			1,894			1,946
	Intangibles with indefinite lives:
	Intellectual property			-			-
	Patent costs			44			44
	Total intangibles with indefinite lives:			44			44
	Total intangible assets, net		$	1,938		$	1,990
	Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense for intangible assets is estimated to be $158 over the remainder of 2015 and $210 in each of the next five years.
	Impairment testing of intangible assets subject to amortization involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. The computed impairment loss is recognized in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows, selection of the appropriate discount rate to measure the risk inherent in future cash flow streams, assessment of an asset’s life cycle, competitive trends impacting the asset as well as other factors. Changes in these underlying assumptions could significantly impact the asset’s estimated fair value.
	Revenue Recognition
	The Company records revenue from product sales when persuasive evidence of an arrangement exists, product has been shipped or delivered, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Product sales represent revenue from the sale of products and related shipping amounts billed to customers, net of promotional discounts, rebates, and return allowances. Depending on individual customer agreements, sales are recognized either upon shipment of product to customers or upon delivery. With respect to direct-to-consumer sales, both title and risk of loss transfer to customers upon our delivery to the customer. The Company’s gross product sales may be subject to sales allowances and deductions in arriving at reported net product sales. For example, we may periodically offer discounts and sales incentives to customers to encourage purchases. Sales incentives are treated as a reduction to the purchase price of the related transaction. Reductions from gross sales for customer discounts and rebates have been minimal, and sales allowances for product returns have not been provided, since under our existing arrangements, customers are not permitted to return product except for non-conforming product.
	Research and Development
	Research and development expenses consist primarily of salaries, benefits, and other related costs, including stock-based compensation, for personnel serving in our research and development functions, and other internal operating expenses, the cost of manufacturing our product for clinical study, the cost of conducting clinical studies and the cost of conducting preclinical and research activities. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are initially capitalized and are then recognized as an expense as the related goods are consumed or the services are performed.
	Shipping and Handling Costs
	The Company records costs of shipping product to our customers in cost of sales. These expenses were $0 and $1 for the three months ended March 31, 2015 and 2014, respectively.
	Stock-based Compensation
	Generally, stock-based payments are measured at their estimated fair value on the date of grant. Stock-based awards to non-employees are re-measured at fair value each financial reporting date until performance is completed. Stock-based compensation expense recognized during a period is based on the estimated number of awards that are ultimately expected to vest. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period.
	The Company uses the Black-Scholes option-pricing model to estimate the fair value of options and the market price of our common stock on the date of grant for the fair value of restricted stock issued. Our determination of fair value of stock-based awards is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate.
	Comprehensive Loss
	Comprehensive income (loss) includes all changes in equity during a period except those that resulted from investments by, or distributions to, the Company’s stockholders. Other comprehensive income (loss) refers to revenues, expenses, gains and losses that are included in comprehensive income (loss), but excluded from net loss as these amounts are recorded directly as an adjustment to stockholders’ equity. The Company had no other comprehensive income (loss) items for the three months ended March 31, 2015 and 2014. Accordingly, the Company's comprehensive loss and net loss are the same for all periods presented.
	Segment Information
	Accounting Standards Codification (“ASC”) 280, Disclosures about Segments of an Enterprise and Related Information, establishes standards for reporting information about operating segments and requires selected information for those segments to be presented in the financial statements. It also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. Management has determined that the Company operates in one segment.
	Fair Value Measurement
	Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby observable and unobservable inputs, used in valuation techniques, are assigned a hierarchical level.
	The following are the hierarchy levels of inputs to measure fair value:
		Level 1:	Inputs that utilize quoted prices (unadjusted) in active markets for identical assets or liabilities.
		Level 2:	Inputs that utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active.
		Level 3:	Inputs that utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity.
	A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. At March 31, 2015 and December 31, 2014, the Company’s financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. Due to their short-term nature, the carrying amounts of the Company’s financial instruments approximated their fair values.
	Basic and Diluted Earnings (Loss) Per Share
Basic net loss per share is computed by dividing net loss available to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potential dilutive securities outstanding had been issued. The Company uses the “treasury stock” method to determine the dilutive effect of common stock equivalents such as options, warrants and restricted stock. For the three months ended March 31, 2015 and 2014, the Company incurred a net loss. Accordingly, the Company’s common stock equivalents were anti-dilutive and excluded from the diluted net loss per share computation. The aggregate number of potentially dilutive common stock equivalents outstanding at March 31, 2015 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,447,115, which includes warrants to purchase an aggregate 958,185 shares of common stock, options to purchase an aggregate of 470,880 shares of common stock and unvested restricted stock awards of 18,050 shares of common stock. The aggregate number of potentially dilutive common stock equivalents outstanding at March 31, 2014 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 777,542, which includes warrants to purchase an aggregate 473,522 shares of common stock, options to purchase an aggregate of 281,820 shares of common stock and unvested restricted stock awards of 22,200 shares of common stock.
Income Taxes
Income taxes are accounted for under the asset and liability method in accordance with ASC 740, “Accounting for Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance to the extent that the recoverability of the asset is unlikely to be recognized.
The Company follows ASC 740 rules governing uncertain tax positions, which provides guidance for recognition and measurement. This prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on recognition, classification and disclosure of these uncertain tax positions. The Company has no uncertain income tax positions.
Interest costs and penalties related to income taxes are classified as interest expense and operating expenses, respectively, in the Company's financial statements. For the three months ended March 31, 2015 and 2014, the Company did not recognize any interest or penalty expense related to income taxes. The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business.
Reclassifications
The Company has revised the presentation of “Selling, general and administrative expenses” within the statements of operations for the three months ended March 31, 2014 to conform to the current year presentation. Research and development expenses of $434 for the three months ended March 31, 2014, were previously not presented separately. This reclassification was for presentation purposes only and had no effect on the financial position, results of operations, or cash flows for the period presented.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2015
Recent Accounting Pronouncements [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 3 – RECENT ACCOUNTING PRONOUNCEMENTS
	In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”), which requires all debt issuance costs be presented in the balance sheet as a direct deduction from the carrying value of the associated debt.  Prior to the issuance of this standard, debt issuance costs, which are specific incremental costs, other than those paid to the lender, that are directly attributable to issuing a debt instrument (i.e., third party costs), were required to be presented in the balance sheet as a deferred charge (i.e., an asset).  Under ASU 2015-03, the presentation of debt issuance costs is consistent with the presentation for a debt discount, (i.e., a direct adjustment to the carrying value of the debt).  ASU 2015-03 does not affect the recognition and measurement of debt issuance costs. Accordingly, the amortization of such costs should continue to be calculated using the interest method and be reported as interest expense.  ASU 2015-03 is effective for us in financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years.  We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.
	In January 2015, the FASB issued ASU No. 2015-01, “Income Statement – Extraordinary and Unusual Items (Subtopic 225-20) – Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items,” (“ASU 2015-01”).  ASU 2015-01 eliminates from U.S. GAAP the concept of extraordinary items and, therefore, it will no longer be necessary for entities to assess items for potential classification as extraordinary items in their financial statements. The accounting changes in ASU 2015-01 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.
	In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). The amendments in this update define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and provides related footnote disclosure requirements. Under U.S. GAAP, financial statements are prepared under the presumption that the reporting organization will continue to operate as a going concern, except in limited circumstances. Financial reporting under this presumption is commonly referred to as the going concern basis of accounting. The going concern basis of accounting establishes the fundamental basis for measuring and classifying assets and liabilities. This update provides guidance on when there is substantial doubt about an organization’s ability to continue as a going concern and how the underlying conditions and events should be disclosed in the footnotes. It is intended to reduce diversity that existed in footnote disclosures because of the lack of guidance about when substantial doubt existed. The amendments in this update are effective for us beginning in the first quarter of 2017. Early application is permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP and requires revenue to be recognized when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for us beginning in the first quarter of 2017 using one of two prescribed transition methods. Early adoption is not permitted. In April 2015, the FASB voted to delay the implementation of ASU 2014-09 by one year. The proposed delay in implementation is not currently effective. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.

Inventories_Net

Inventories, Net	3 Months Ended
	Mar. 31, 2015
Inventories, Net [Abstract]
INVENTORIES, NET	NOTE 4 – INVENTORIES, NET
	Inventories, net at March 31, 2015 and December 31, 2014 consisted of the following:
	(In thousand $)	March 31,			December 31,
		2015			2014
	Raw materials	$	1,638		$	1,638
	Work in process		2			2
	Finished goods		435			443
			2,075			2,083
	Less: inventory reserves		(265	)		(269	)
	Inventories, net	$	1,810		$	1,814

Fixed_Assets

Fixed Assets	3 Months Ended
	Mar. 31, 2015
Fixed Assets [Abstract]
FIXED ASSETS	NOTE 5 – FIXED ASSETS
	Fixed assets at March 31, 2015 and December 31, 2014 consisted of the following:
	(In thousand $)	March 31,			December 31,
		2015			2014
	Furniture, fixtures and equipment	$	134		$	134
	Computers and software		28			21
	Leasehold improvements		239			239
	Other		7			7
	Total fixed assets		408			401
	Less: accumulated depreciation and amortization		(100	)		(88	)
	Net book value of fixed assets	$	308		$	313
	Depreciation and amortization expense was $12 and $12 for the three months ended March 31, 2015 and 2014, respectively. Repairs and maintenance costs are expensed as incurred.

Debt

Debt	3 Months Ended
	Mar. 31, 2015
Debt [Abstract]
DEBT	NOTE 6 – DEBT
	Revolving Note
	On August 29, 2014, the Company entered into a Loan Revision Agreement, which extended the termination date of the October 2013 revolving credit agreement (as amended, the “Revolving Note”) with City National Bank to August 31, 2015. All other terms evidenced by the Revolving Note remained the same. The Revolving Note provides an aggregate principal amount of $500 in revolving loans collateralized by all inventory, chattel paper, accounts, equipment, general intangibles, securities and instruments. The revolving loans may be borrowed, repaid and re-borrowed, provided at the time of any borrowing no event of default exists. Under the Revolving Note, all principal amounts outstanding with interest thereon is due and payable on August 31, 2015. Committed borrowings under the Revolving Note bear interest from the date of its disbursement at a per annum interest rate equal to prime rate plus 1.25%. The Revolving Note contains customary events of default, including failure to make payment and bankruptcy. At March 31, 2015 and December 31, 2014, there were no outstanding borrowings under the Revolving Note. On April 1, 2015, we borrowed $500 under the Revolving Note, leaving $0 of borrowings still available to the Company under the Revolving Note.

Prepaid_Expenses_Other_Current

Prepaid Expenses, Other Current Assets and Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Prepaid Expenses, Other Current Assets and Accrued Expenses [Abstract]
PREPAID EXPENSES, OTHER CURRENT ASSETS AND ACCRUED EXPENSES	NOTE 7 - PREPAID EXPENSES, OTHER CURRENT ASSETS AND ACCRUED EXPENSES
	Prepaid Expenses and Other Current Assets
	Prepaid expenses and other current assets consist of various payments that the Company has made in advance for goods or services to be received in the future. Prepaid expenses and other current assets at March 31, 2015 and December 31, 2014 consisted of the following:
	(In thousand $)	March 31,		December 31,
		2015		2014
	Prepaid insurance	$	84	$	46
	Prepaid research and development		6		15
	Prepaid consulting		8		8
	Prepaid inventory purchases		682		664
	Other		21		12
	Total prepaid expenses and other current assets	$	801	$	745
	Accrued Expenses
	Accrued expenses consist of estimated future liability payments that relate to the current and prior accounting periods. Management reviews these estimates regularly to determine their reasonableness. Accrued expenses at March 31, 2015 and December 31, 2014 consisted of the following:
	(In thousand $)	March 31,		December 31,
		2015		2014
	Advertising and promotional expense payable	$	171	$	171
	Audit fees payable		68		25
	Deferred rent		56		30
	Research & development		20		49
	Accrued salaries & bonuses		-		92
	Consulting fees payable		21		96
	Other accrued expenses		14		32
	Total accrued expenses	$	350	$	495

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 8 – STOCKHOLDERS’ EQUITY
	Changes in stockholders’ equity for the three months ended March 31, 2015 were as follows:
							Additional					Total
		Common Stock					paid-in		Accumulated			stockholders'
	(In thousand $)	Shares			Amount		capital		deficit			equity
	Balance at December 31, 2014		3,103,300		$	3	$	25,100	$	(18,367	)	$	6,736
	Forfeiture of prior shares issued for services		(1,000	)		-		-		-			-
	Stock-based compensation expense		-			-		287		-			287
	Net loss		-			-		-		(1,529	)		(1,529	)
	Balance at March 31, 2015		3,102,300		$	3	$	25,387	$	(19,896	)	$	5,494
	Issuances of Common Stock
	The Company has periodically issued common stock in connection with certain private and public offerings. The Company has received aggregate gross proceeds of approximately $15.9 million from these offerings as follows:
	(In thousand $)				Gross
	Date	Shares			Proceeds
	25-Feb-11		95,334		$	1,430
	31-May-11		28,200			423
	27-Jun-11		37,500			563
	12-Jul-11		1,667			25
	2-Dec-11		4,000			40
	10-Feb-12		65,000			325
	14-Feb-12		80,000			400
	7-Mar-12		20,000			100
	15-Mar-12		35,000			175
	22-Mar-12		5,000			25
	9-Apr-12		20,000			100
	April 24, 2012*		4,000			-
	28-Jun-12		48,000			600
	6-Jul-12		411,600			5,145
	27-Jan-14		631,346			4,735
	19-Nov-14		193,865			1,816
			1,680,512		$	15,902
	* Shares issued under price protection agreement

Warrants

Warrants	3 Months Ended
	Mar. 31, 2015
Warrants [Abstract]
WARRANTS	NOTE 9 - WARRANTS
	On January 27, 2014, in connection with a private placement transaction, the Company granted warrants to purchase an aggregate of 473,522 shares of common stock as follows: (i) Series A warrants to purchase 315,676 shares of common stock at an exercise price of $15.00 per share (the “Series A Warrant”) and (ii) Series B warrants to purchase 157,846 shares of common stock at an exercise price of $45.00 per share (the “Series B Warrant”). The warrants were determined to have an estimated aggregate fair value of $2,486 at issuance. The Series A Warrants entitle the holders to purchase shares of common stock for a period of three years from the grant date and the Series B Warrants entitle the holders to purchase common stock for a period of five years from the grant date. The warrants can also be exercised on a cashless basis.
	On November 19, 2014 in connection with a registered direct public offering, the Company granted warrants to purchase an aggregate of 484,663 shares of common stock as follows: (i) Series C warrants entitle the holders to purchase an aggregate of 145,399 shares of common stock at an exercise price of $12.00 per share for a period of 66-months from the grant date (the “Series C Warrant”), (ii) Series D warrants entitle the holders to purchase an aggregate of 193,865 shares of common stock at an exercise price of $9.37 per share for a period of 6-months from the grant date (the “Series D Warrant”), and (iii) Series E warrants entitle the holders to purchase an aggregate of 145,399 shares of common stock at an exercise price of $15.00 per share for a period of 90-months from the grant date (the “Series E Warrant). Each Series E Warrant will be exercisable only if the Series D Warrants are exercised. The Series C, Series D and Series E Warrants were determined to have an estimated aggregate fair value of $969, $470, and $1,048 at issuance, respectively. In addition, the Company is required to issue to the purchasers up to 193,865 additional shares of common stock in the event that the closing price of our common stock is below $14.06 (subject to adjustment) on the twelve month anniversary of the date of issuance, provided that the purchasers continue to hold at least a portion of the shares of common stock issued in the offering on such date (the “Make-Whole Shares”). The Make-Wholes Shares were determined to have an estimated fair value of $1,049 at issuance.
	The following table summarizes information about warrants outstanding and exercisable at March 31, 2015:
				Number of		Shares Underlying		Shares Underlying		Shares Underlying
								Warrants		Warrants
				Shares		Warrants		Outstanding		Exercisable
				Underlying		Exchanged,		at		at					Expiration
				Warrants		Exercised		March 31,		March 31,		Exercise			Term in
	Description		Grant Date	Granted		or Expired		2015		2015		Price			Years
	Series A(1)		27-Jan-14		315,676		-		315,676		315,676	$	15			1.83
	Series B(1)		27-Jan-14		157,846		-		157,846		157,846	$	45			3.82
	Series C(2)		19-Nov-14		145,399		-		145,399		-	$	12			5.13
	Series D(2)		19-Nov-14		193,865		-		193,865		193,865	$	9.37			0.13
	Series E(2)		19-Nov-14		145,399		-		145,399		-	$	15			7.13
					958,185		-		958,185		667,387
		-1	Issued in connection with the January 27, 2014 private placement transaction.
		-2	Issued in connection with the November 19, 2014 registered-direct public offering.
	The following table summarizes the assumptions used to value the warrants at the issuance date using the Black-Scholes option pricing model:
				Number of Shares		Stock
				Underlying		Price on												Risk
				Warrants		Measurement		Exercise		Expected		Expected			Dividend			Free
	Description		Grant Date	Granted		Date		Price		Term		Volatility			Yield			Rate
	Series A		27-Jan-14		315,676	$	7	$	15		3		150	%		0	%		0.76	%
	Series B		27-Jan-14		157,846	$	7	$	45		5		150	%		0	%		1.61	%
	Series C		19-Nov-14		145,399	$	9.37	$	12		5.5		94.6	%		0	%		1.64	%
	Series D		19-Nov-14		193,865	$	9.37	$	9.37		0.5		93.44	%		0	%		0.07	%
	Series E		19-Nov-14		145,399	$	9.37	$	15		7.5		94.6	%		0	%		1.64	%
					958,185

Stock_Compensation

Stock Compensation	3 Months Ended
	Mar. 31, 2015
Stock Compensation [Abstract]
STOCK COMPENSATION	NOTE 10 - STOCK COMPENSATION
	The Company’s 2012 Equity Incentive Plan (as amended, the “Plan”) provides for the issuance of up to 550,000 shares of our common stock. The Plan provides for grants of stock options, stock appreciation rights, restricted stock, other stock-based awards and other cash-based awards. As of March 31, 2015, the remaining shares of common stock available for future issuance of awards was 109,120. The Company granted an aggregate of 30,000 options to purchase restricted common stock to certain directors prior to the adoption of the Plan.
	Stock Option
	The following table summarizes stock option activity for the three months ended March 31, 2015:
											Weighted
							Weighted				Average
			Shares				Average				Remaining
			Under				Exercise				Contractual
			Options				Price				Term (Years)
	Balance at December 31, 2014			367,080			$	14.68				8.5
	Options granted			108,000				12.5
	Options exercised			-				-
	Options cancelled/forfeited			(4,200	)			(10.00	)
	Balance at March 31, 2015			470,880			$	14.22				8.61
	The weighted average grant date fair value of stock options granted during the three months ended March 31, 2015 was $5.22. The following table summarizes the assumptions used to value stock options granted during the three months ended March 31, 2015 using a Black-Scholes model:
	Expected volatility			98	%
	Risk-free interest rate			1.39%-1.69	%
	Expected term in years			5.8-6.3
	Expected dividend yield			0	%
	The risk-free rate is based on the U.S. Treasury rate for a note with a similar term in effect at the time of the grant. The expected volatility is based on the volatility of the Company’s historical stock prices.
	At March 31, 2015, the aggregate intrinsic value of outstanding and exercisable options was $0. The aggregate intrinsic value is calculated by multiplying the number of outstanding and exercisable options by the excess of the market price for our common stock at March 31, 2015 over the exercise price for each option. At March 31, 2015, the market price for our common stock was $4.58.
	The following table summarizes information about options outstanding and exercisable at March 31, 2015:
	Options Outstanding												Options Exercisable
									Weighted Average								Weighted Average
	Range of				Options				Remaining				Range of		Options		Remaining
	Exercise Price				Outstanding				Contractual Life				Exercise Price		Exercisable		Contractual Life
	$	7				5,000				7.14			$	7		5,000		7.14
	$	8.6				30,500				8.95			$	8.6		15,250		8.95
	$	10				5,120				7.86			$	10		5,120		7.86
	$	11				3,000				7.78			$	11		3,000		7.78
	$	12.1				30,500				9.11			$	12.1		7,625		9.11
	$	12.5				214,200				9.01			$	12.5		94,425		8.26
	$	12.55				20,000				9.14			$	12.55		-		-
	$	13				14,600				9.28			$	13		3,650		9.28
	$	13.45				2,000				9.23			$	13.45		-		-
	$	13.5				14,960				9.24			$	13.5		-		-
	$	13.75				6,000				9.43			$	13.75		1,500		9.43
	$	17.5				100,000				7.86			$	17.5		100,000		7.86
	$	22.5				5,000				6.37			$	22.5		5,000		6.37
	$	32				15,000				6.28			$	32		15,000		6.28
	$	34.5				5,000				6.31			$	34.5		5,000		6.31
						470,880										260,570
	As of March 31, 2015, there were 210,310 remaining unvested options, with vesting terms ranging from 0.1 to 3.8 years. As of March 31, 2015, vested options had a weighted-average remaining contractual term of 8.0 years and a weighted-average exercise price of $15.76 per share.
	Restricted Stock
	The following table summarizes restricted stock awards activities during the three months ended March 31, 2015:
							Weighted
							Average
							Grant Date
			Shares				Share Price
	Restricted stock awards unvested at December 31, 2014			22,200			$	14.95
	Granted			-				-
	Vested			(3,150	)			7.75
	Forfeited			(1,000	)			7.5
	Restricted stock awards unvested at March 31, 2015			18,050			$	16.62
	At March 31, 2015, the weighted-average remaining vesting period of unvested restricted stock awards was 1.67 years.
	Stock-Based Compensation:
	For the three months ended March 31, 2015 and 2014, stock-based compensation was $287 and $303, respectively, which consists of expenses related to the issuance of stock options and restricted stock. The following table summarizes the components of stock-based compensation included in the statements of operations for the three months ended March 31, 2015 and 2014:
			Three months ended
			March 31,
			2015				2014
	Cost of sales		$	-			$	-
	Research and development			25				19
	Selling, general and administrative			262				284
	Total stock-based compensation		$	287			$	303
The aggregate unrecognized compensation expense of stock options and restricted stock at March 31, 2015 was $1,470, which will be recognized through January 2019.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Taxes [Abstract]
INCOME TAXES	NOTE 11 - INCOME TAXES
	Due to the Company’s history of losses and uncertainty of future taxable income, a valuation allowance has been established to fully offset net operating losses and other deferred tax assets. The valuation allowance will be maintained until sufficient positive evidence exists to support that it is no longer necessary. The Company is liable for various state minimum taxes which are immaterial.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 – COMMITMENTS AND CONTINGENCIES
	Operating Lease
	The Company leases its corporate offices under an operating lease. The office space consists of approximately 14,304 square feet. The term of the lease is five years commencing on January 1, 2015 and expiring on December 31, 2019. We have two options to renew our lease for an additional three years each.
	At March 31, 2015, the future minimum lease payments under the non-cancellable operating lease in excess of one year is as follows:
	(In thousand $)
	Years Ended December 31,	Amount
	2015 (remaining nine months)	$	134
	2016		152
	2017		181
	2018		187
	2019		191
	Total	$	845
	Rent expense including common area maintenance charges and taxes for the three months ended March 31, 2015 and 2014 was $55 and $17, respectively.
	Defined Contribution Plan
	The Company established a 401(K) Plan (the “401(K) Plan”) for eligible employees of the Company effective April 1, 2014. Generally, all employees of the Company who are at least twenty-one years of age and who have completed three months of service are eligible to participate in the 401(K) Plan. The 401(K) Plan is a defined contribution plan that provides that participants may make salary deferral contributions, of up to the statutory maximum allowed by law (subject to make-up contributions) in the form of voluntary payroll deductions. The Company’s matching contribution is equal to 100 percent on the first four percent of a participant’s compensation which is deferred as an elective deferral. The Company’s aggregate matching contribution for the three months ended March 31, 2015 and 2014 were $14 and $0, respectively.
	Supply Agreement
	Pursuant to the Exclusive Supply Agreement (as amended, the “Agreement”) with DIL, DIL manufactures and supplies Fortetropin exclusively to the Company and may not manufacture Fortetropin for other entities. In exchange the Company agreed to purchase minimum quantities of Fortetropin at fixed prices through 2016. In addition, DIL agreed to assign its United States patent application for the manufacture of the formula to the Company and the Company agreed, for a period of seven years from the expiration of the Agreement, it will pay DIL a low single-digit royalty payment for each kilogram of Fortetropin produced by the Company, subject to certain minimum and maximum amounts. DIL also granted the Company a right of first refusal to license and/or acquire the European patent it owns for the manufacture of the formula. The Agreement expires on December 31, 2016, and may be renewed for additional one-year periods unless terminated by either party by giving ninety days notice before the expiration of the current term. Included in prepaid expenses and other current assets at March 31, 2015 were payments of $663 that the Company paid in advance for 2014 inventory purchases yet to be delivered by DIL. The minimum purchase obligations under the agreement are €1,969, or approximately $2,137, in 2015 (including 2014 and first quarter 2015 purchase commitments of €241, or approximately $262, and €432, or approximately $469, respectively, that were not yet made) and €1,728, or approximately $1,875, in 2016. Our failure to meet the 2014 and first quarter 2015 minimum purchase commitments could be considered a material breach under the terms of the agreement, and DIL can seek to terminate the agreement. Upon receipt of written notice of a material breach, the Company would have sixty days to fulfill the purchase requirements. If we do not cure the breach within sixty days, DIL may terminate the Agreement immediately upon sending us written notification. If the Agreement is terminated, DIL may seek to invalidate the assignment of the patent application, which could cause us to incur significant expenses to defend against such claim. If DIL is successful in invalidating the assignment of the patent application, we may be limited from manufacturing, selling or using Fortetropin, which may adversely impact our business, financial condition and results of operations.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Summary of Significant Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
	The accompanying unaudited interim condensed consolidated financial statements include the accounts of MYOS Corporation and its wholly-owned subsidiary, Atlas Acquisition Corp. All material intercompany balances and transactions between and among its consolidated subsidiary have been eliminated.
Estimates	Estimates
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, equity and the disclosures of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates. Significant items subject to such estimates include but are not limited to the valuation of stock-based awards, revenue recognition, measurement of allowances for doubtful accounts and inventory reserves, the selection of asset useful lives, fair value estimations used to test long-lived assets, including intangibles, impairments and provisions necessary for assets and liabilities.
	The Company has not recorded sales to its distributors during the first quarter 2015 and fourth quarter 2014, and sales to distributors were minimal during the third quarter 2014, accordingly the Company cannot predict what future sales, if any, will come from its distributors. In addition, the Company recently launched its direct-to-consumer branded products. Management’s estimates, including evaluation of impairment of long-lived assets and inventory reserves are based in part on forecasted future results. A variety of factors could cause actual results to differ from forecasted results and these differences could have a significant effect on asset carrying amounts.
Cash & Cash Equivalents	Cash and Cash Equivalents
	As of March 31, 2015 and December 31, 2014, the Company had cash of $590 and $1,567, respectively. The Company considers all highly liquid investments purchased with a maturity of three months or less and money market accounts to be cash equivalents. At March 31, 2015 and December 31, 2014, the Company had no cash equivalents.
	The Company maintains its bank accounts with high credit quality financial institutions and has never experienced any losses related to these bank accounts. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its financial institutions. The balance at times may exceed federally insured limits. At March 31, 2015 and December 31, 2014, the Company's uninsured cash balances totaled $309 and $1,292, respectively.
Concentrations of Risk, Significant Customers and Significant Supplier	Concentrations of Risk, Significant Customers and Significant Supplier
	Management regularly reviews accounts receivable and if necessary, establishes an allowance for doubtful accounts that reflects management’s best estimate of amounts that may not be collectible based on historical collection experience and specific customer information. Bad debt expense recognized as a result of an allowance for doubtful accounts is classified under selling, general and administrative expenses in the statements of operations. Bad debt expense was $0 for the three months ended March 31, 2015 and 2014.
	At March 31, 2015 and December 31, 2014, the Company had the following concentrations of net accounts receivable with customers:
			March 31,			December 31,
	(In thousand $)		2015			2014
	Cenegenics		$	1,072		$	1,372
	Allowance for doubtful accounts			(390	)		(390	)
	Accounts receivable, net		$	682		$	982
	If we are unable to collect our outstanding accounts receivable from Cenegenics, our operating results and financial condition will be adversely affected.
	The Company currently relies on one third-party manufacturer to produce Fortetropin (see NOTE 12 – Commitments and Contingencies - Supply Agreement). This manufacturer purchases all the needed raw materials from suppliers and coordinates any additional production steps with third-parties. We have multiple vendors for blending, packaging and labeling. The Company is pursuing other supply alternatives.
Inventories, net	Inventories, net
	Inventories are valued at the lower of cost or market, with cost determined on a first in, first-out basis. The Company writes down inventories to net realizable value based on forecasted demand, market conditions or other factors.
Fixed Assets	Fixed Assets
	Fixed assets are stated at cost and depreciated to their estimated residual value over their estimated useful lives of 3 to 7 years. Leasehold improvements are amortized over the lesser of the asset's useful life or the contractual remaining lease term including expected renewals. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are reversed from the accounts and the resulting gains or losses are included in the statements of operations.
	Depreciation is provided using the straight-line method for all fixed assets.
	We review our fixed assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. If the assets are determined to be unrecoverable, an impairment loss is calculated by determining the difference between the carrying values and the estimated fair value. We did not consider any of our fixed assets to be impaired during the three months ended March 31, 2015 and 2014.
Intangible Assets	Intangible Assets
	The Company’s intangible assets consist primarily of intellectual property pertaining to Fortetropin, including its formula, trademarks, trade secrets, patent application and domain names, which was determined to have a fair value of $2,000 as of December 31, 2011. Based on expansion into new markets and introduction of new formulas, management determined that the intellectual property had a finite useful life of ten (10) years and began amortizing the asset over its estimated useful life beginning April 2014. There were no impairment losses recorded during the three months ended March 31, 2015 and 2014.
	In July 2014, the Company acquired the United States patent application for the manufacture of Fortetropin from Deutsches Institut fur Lebensmitteltechnik e.V. - the German Institute for Food Technologies (“DIL”). The cost of the patent application, which was capitalized as an intangible asset, was determined to be $101, based on the present value of the minimum guaranteed royalty payable to DIL using a discount rate of 10%. The intangible asset will be amortized over an estimated useful life of ten (10) years. The remaining contingent royalty payments will be recorded as the contingency is resolved and the royalty becomes payable under the arrangement. For additional information on the amended supply agreement with DIL refer to “NOTE 12 – Commitments and Contingencies - Supply Agreement.”
	Intangible assets also includes patent costs associated with applying for a patent and being issued a patent. Costs to defend a patent and costs to invalidate a competitor’s patent or patent application are expensed as incurred. Upon issuance of the patent, capitalized patent costs are reclassified from intangibles with indefinite lives to intangibles with finite lives and amortized on a straight-line basis over the shorter of the estimated economic life or the initial term of the patent, generally 20 years.
	Intangible assets at March 31, 2015 and December 31, 2014 consisted of the following:
			March 31,			December 31,
	(In thousand $)		2015			2014
	Intangibles with finite lives:
	Intellectual property		$	2,101		$	2,101
	Less: accumulated amortization			(207	)		(155	)
	Total intangibles with finite lives:			1,894			1,946
	Intangibles with indefinite lives:
	Intellectual property			-			-
	Patent costs			44			44
	Total intangibles with indefinite lives:			44			44
	Total intangible assets, net		$	1,938		$	1,990
	Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense for intangible assets is estimated to be $158 over the remainder of 2015 and $210 in each of the next five years.
	Impairment testing of intangible assets subject to amortization involves comparing the carrying amount of the asset to the forecasted undiscounted future cash flows whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. The computed impairment loss is recognized in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows, selection of the appropriate discount rate to measure the risk inherent in future cash flow streams, assessment of an asset’s life cycle, competitive trends impacting the asset as well as other factors. Changes in these underlying assumptions could significantly impact the asset’s estimated fair value.
Revenue Recognition	Revenue Recognition
	The Company records revenue from product sales when persuasive evidence of an arrangement exists, product has been shipped or delivered, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Product sales represent revenue from the sale of products and related shipping amounts billed to customers, net of promotional discounts, rebates, and return allowances. Depending on individual customer agreements, sales are recognized either upon shipment of product to customers or upon delivery. With respect to direct-to-consumer sales, both title and risk of loss transfer to customers upon our delivery to the customer. The Company’s gross product sales may be subject to sales allowances and deductions in arriving at reported net product sales. For example, we may periodically offer discounts and sales incentives to customers to encourage purchases. Sales incentives are treated as a reduction to the purchase price of the related transaction. Reductions from gross sales for customer discounts and rebates have been minimal, and sales allowances for product returns have not been provided, since under our existing arrangements, customers are not permitted to return product except for non-conforming product.
Research and Development	Research and Development
	Research and development expenses consist primarily of salaries, benefits, and other related costs, including stock-based compensation, for personnel serving in our research and development functions, and other internal operating expenses, the cost of manufacturing our product for clinical study, the cost of conducting clinical studies and the cost of conducting preclinical and research activities. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are initially capitalized and are then recognized as an expense as the related goods are consumed or the services are performed.
Shipping and Handling Costs	Shipping and Handling Costs
	The Company records costs of shipping product to our customers in cost of sales. These expenses were $0 and $1 for the three months ended March 31, 2015 and 2014, respectively.
Stock-based Compensation	Stock-based Compensation
	Generally, stock-based payments are measured at their estimated fair value on the date of grant. Stock-based awards to non-employees are re-measured at fair value each financial reporting date until performance is completed. Stock-based compensation expense recognized during a period is based on the estimated number of awards that are ultimately expected to vest. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period.
	The Company uses the Black-Scholes option-pricing model to estimate the fair value of options and the market price of our common stock on the date of grant for the fair value of restricted stock issued. Our determination of fair value of stock-based awards is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate.
Comprehensive Loss	Comprehensive Loss
	Comprehensive income (loss) includes all changes in equity during a period except those that resulted from investments by, or distributions to, the Company’s stockholders. Other comprehensive income (loss) refers to revenues, expenses, gains and losses that are included in comprehensive income (loss), but excluded from net loss as these amounts are recorded directly as an adjustment to stockholders’ equity. The Company had no other comprehensive income (loss) items for the three months ended March 31, 2015 and 2014. Accordingly, the Company's comprehensive loss and net loss are the same for all periods presented.
Segment Information	Segment Information
	Accounting Standards Codification (“ASC”) 280, Disclosures about Segments of an Enterprise and Related Information, establishes standards for reporting information about operating segments and requires selected information for those segments to be presented in the financial statements. It also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. Management has determined that the Company operates in one segment.
Fair Value Measurement	Fair Value Measurement
	Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby observable and unobservable inputs, used in valuation techniques, are assigned a hierarchical level.
	The following are the hierarchy levels of inputs to measure fair value:
		Level 1:	Inputs that utilize quoted prices (unadjusted) in active markets for identical assets or liabilities.
		Level 2:	Inputs that utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active.
		Level 3:	Inputs that utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity.
	A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. At March 31, 2015 and December 31, 2014, the Company’s financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. Due to their short-term nature, the carrying amounts of the Company’s financial instruments approximated their fair values.
Basic and Diluted Loss Per Share	Basic and Diluted Earnings (Loss) Per Share
	Basic net loss per share is computed by dividing net loss available to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potential dilutive securities outstanding had been issued. The Company uses the “treasury stock” method to determine the dilutive effect of common stock equivalents such as options, warrants and restricted stock. For the three months ended March 31, 2015 and 2014, the Company incurred a net loss. Accordingly, the Company’s common stock equivalents were anti-dilutive and excluded from the diluted net loss per share computation. The aggregate number of potentially dilutive common stock equivalents outstanding at March 31, 2015 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,447,115, which includes warrants to purchase an aggregate 958,185 shares of common stock, options to purchase an aggregate of 470,880 shares of common stock and unvested restricted stock awards of 18,050 shares of common stock. The aggregate number of potentially dilutive common stock equivalents outstanding at March 31, 2014 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 777,542, which includes warrants to purchase an aggregate 473,522 shares of common stock, options to purchase an aggregate of 281,820 shares of common stock and unvested restricted stock awards of 22,200 shares of common stock.
Income Taxes	Income Taxes
	Income taxes are accounted for under the asset and liability method in accordance with ASC 740, “Accounting for Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the periods in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance to the extent that the recoverability of the asset is unlikely to be recognized.
	The Company follows ASC 740 rules governing uncertain tax positions, which provides guidance for recognition and measurement. This prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on recognition, classification and disclosure of these uncertain tax positions. The Company has no uncertain income tax positions.
	Interest costs and penalties related to income taxes are classified as interest expense and operating expenses, respectively, in the Company's financial statements. For the three months ended March 31, 2015 and 2014, the Company did not recognize any interest or penalty expense related to income taxes. The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business.
Reclassifications	Reclassifications
	The Company has revised the presentation of “Selling, general and administrative expenses” within the statements of operations for the three months ended March 31, 2014 to conform to the current year presentation. Research and development expenses of $434 for the three months ended March 31, 2014, were previously not presented separately. This reclassification was for presentation purposes only and had no effect on the financial position, results of operations, or cash flows for the period presented.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Concentration Risk [Line Items]
Summary of Intangible Assets		March 31,			December 31,
	(In thousand $)	2015			2014
	Intangibles with finite lives:
	Intellectual property	$	2,101		$	2,101
	Less: accumulated amortization		(207	)		(155	)
	Total intangibles with finite lives:		1,894			1,946
	Intangibles with indefinite lives:
	Intellectual property		-			-
	Patent costs		44			44
	Total intangibles with indefinite lives:		44			44
	Total intangible assets, net	$	1,938		$	1,990
Accounts receivable [Member]
Concentration Risk [Line Items]
Schedule of concentrations of net accounts receivable with customers		March 31,			December 31,
	(In thousand $)	2015			2014
	Cenegenics	$	1,072		$	1,372
	Allowance for doubtful accounts		(390	)		(390	)
	Accounts receivable, net	$	682		$	982

Inventories_Net_Tables

Inventories, Net (Tables)	3 Months Ended
	Mar. 31, 2015
Inventories, Net [Abstract]
Summary of Inventory	(In thousand $)	March 31,			December 31,
		2015			2014
	Raw materials	$	1,638		$	1,638
	Work in process		2			2
	Finished goods		435			443
			2,075			2,083
	Less: inventory reserves		(265	)		(269	)
	Inventories, net	$	1,810		$	1,814

Fixed_Assets_Tables

Fixed Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Fixed Assets [Abstract]
Schedule of fixed assets	(In thousand $)	March 31,			December 31,
		2015			2014
	Furniture, fixtures and equipment	$	134		$	134
	Computers and software		28			21
	Leasehold improvements		239			239
	Other		7			7
	Total fixed assets		408			401
	Less: accumulated depreciation and amortization		(100	)		(88	)
	Net book value of fixed assets	$	308		$	313

Prepaid_Expenses_Other_Current1

Prepaid Expenses, Other Current Assets and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Prepaid Expenses, Other Current Assets and Accrued Expenses [Abstract]
Summary of prepaid expenses and other current assets	(In thousand $)	March 31,		December 31,
		2015		2014
	Prepaid insurance	$	84	$	46
	Prepaid research and development		6		15
	Prepaid consulting		8		8
	Prepaid inventory purchases		682		664
	Other		21		12
	Total prepaid expenses and other current assets	$	801	$	745
Summary of accrued expenses	(In thousand $)	March 31,		December 31,
		2015		2014
	Advertising and promotional expense payable	$	171	$	171
	Audit fees payable		68		25
	Deferred rent		56		30
	Research & development		20		49
	Accrued salaries & bonuses		-		92
	Consulting fees payable		21		96
	Other accrued expenses		14		32
	Total accrued expenses	$	350	$	495

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity [Abstract]
Schedule of changes in stockholders equity							Additional					Total
		Common Stock					paid-in		Accumulated			stockholders'
	(In thousand $)	Shares			Amount		capital		deficit			equity
	Balance at December 31, 2014		3,103,300		$	3	$	25,100	$	(18,367	)	$	6,736
	Forfeiture of prior shares issued for services		(1,000	)		-		-		-			-
	Stock-based compensation expense		-			-		287		-			287
	Net loss		-			-		-		(1,529	)		(1,529	)
	Balance at March 31, 2015		3,102,300		$	3	$	25,387	$	(19,896	)	$	5,494
Schedule of periodical gross proceeds from private placements	(In thousand $)				Gross
	Date	Shares			Proceeds
	25-Feb-11		95,334		$	1,430
	31-May-11		28,200			423
	27-Jun-11		37,500			563
	12-Jul-11		1,667			25
	2-Dec-11		4,000			40
	10-Feb-12		65,000			325
	14-Feb-12		80,000			400
	7-Mar-12		20,000			100
	15-Mar-12		35,000			175
	22-Mar-12		5,000			25
	9-Apr-12		20,000			100
	April 24, 2012*		4,000			-
	28-Jun-12		48,000			600
	6-Jul-12		411,600			5,145
	27-Jan-14		631,346			4,735
	19-Nov-14		193,865			1,816
			1,680,512		$	15,902
	* Shares issued under price protection agreement

Warrants_Tables

Warrants (Tables) (Warrants [Member])	3 Months Ended
	Mar. 31, 2015
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of warrants issued to private placement				Number of		Shares Underlying		Shares Underlying		Shares Underlying
								Warrants		Warrants
				Shares		Warrants		Outstanding		Exercisable
				Underlying		Exchanged,		at		at					Expiration
				Warrants		Exercised		March 31,		March 31,		Exercise			Term in
	Description		Grant Date	Granted		or Expired		2015		2015		Price			Years
	Series A(1)		27-Jan-14		315,676		-		315,676		315,676	$	15			1.83
	Series B(1)		27-Jan-14		157,846		-		157,846		157,846	$	45			3.82
	Series C(2)		19-Nov-14		145,399		-		145,399		-	$	12			5.13
	Series D(2)		19-Nov-14		193,865		-		193,865		193,865	$	9.37			0.13
	Series E(2)		19-Nov-14		145,399		-		145,399		-	$	15			7.13
					958,185		-		958,185		667,387
		-1	Issued in connection with the January 27, 2014 private placement transaction.
		-2	Issued in connection with the November 19, 2014 registered-direct public offering.
Summary of assumptions used to value warrants using Black-Scholes option pricing model				Number of Shares		Stock
				Underlying		Price on												Risk
				Warrants		Measurement		Exercise		Expected		Expected			Dividend			Free
	Description		Grant Date	Granted		Date		Price		Term		Volatility			Yield			Rate
	Series A		27-Jan-14		315,676	$	7	$	15		3		150	%		0	%		0.76	%
	Series B		27-Jan-14		157,846	$	7	$	45		5		150	%		0	%		1.61	%
	Series C		19-Nov-14		145,399	$	9.37	$	12		5.5		94.6	%		0	%		1.64	%
	Series D		19-Nov-14		193,865	$	9.37	$	9.37		0.5		93.44	%		0	%		0.07	%
	Series E		19-Nov-14		145,399	$	9.37	$	15		7.5		94.6	%		0	%		1.64	%
					958,185

Stock_Compensation_Tables

Stock Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of restricted stock award activities							Weighted
							Average
							Grant Date
			Shares				Share Price
	Restricted stock awards unvested at December 31, 2014			22,200			$	14.95
	Granted			-				-
	Vested			(3,150	)			7.75
	Forfeited			(1,000	)			7.5
	Restricted stock awards unvested at March 31, 2015			18,050			$	16.62
Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of stock option activities											Weighted
							Weighted				Average
			Shares				Average				Remaining
			Under				Exercise				Contractual
			Options				Price				Term (Years)
	Balance at December 31, 2014			367,080			$	14.68				8.5
	Options granted			108,000				12.5
	Options exercised			-				-
	Options cancelled/forfeited			(4,200	)			(10.00	)
	Balance at March 31, 2015			470,880			$	14.22				8.61
Summary of assumptions used to value stock options granted using a Black-Scholes model	Expected volatility			98	%
	Risk-free interest rate			1.39%-1.69	%
	Expected term in years			5.8-6.3
	Expected dividend yield			0	%
Summary of option outstanding and exercisable	Options Outstanding												Options Exercisable
									Weighted Average								Weighted Average
	Range of				Options				Remaining				Range of		Options		Remaining
	Exercise Price				Outstanding				Contractual Life				Exercise Price		Exercisable		Contractual Life
	$	7				5,000				7.14			$	7		5,000		7.14
	$	8.6				30,500				8.95			$	8.6		15,250		8.95
	$	10				5,120				7.86			$	10		5,120		7.86
	$	11				3,000				7.78			$	11		3,000		7.78
	$	12.1				30,500				9.11			$	12.1		7,625		9.11
	$	12.5				214,200				9.01			$	12.5		94,425		8.26
	$	12.55				20,000				9.14			$	12.55		-		-
	$	13				14,600				9.28			$	13		3,650		9.28
	$	13.45				2,000				9.23			$	13.45		-		-
	$	13.5				14,960				9.24			$	13.5		-		-
	$	13.75				6,000				9.43			$	13.75		1,500		9.43
	$	17.5				100,000				7.86			$	17.5		100,000		7.86
	$	22.5				5,000				6.37			$	22.5		5,000		6.37
	$	32				15,000				6.28			$	32		15,000		6.28
	$	34.5				5,000				6.31			$	34.5		5,000		6.31
						470,880										260,570
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of stock-based compensation			Three months ended
			March 31,
			2015				2014
	Cost of sales		$	-			$	-
	Research and development			25				19
	Selling, general and administrative			262				284
	Total stock-based compensation		$	287			$	303

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies [Abstract]
Summary of future minimum lease payments under the non-cancelable operating lease	(In thousand $)
	Years Ended December 31,	Amount
	2015 (remaining nine months)	$	134
	2016		152
	2017		181
	2018		187
	2019		191
	Total	$	845

Nature_of_Operations_Basis_of_1

Nature of Operations, Basis of Presentation and Liquidity (Details) (USD $)	3 Months Ended		96 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Nature of Operations and Basis of Presentation (Textual)
Revenue	$6	$1,546	$7,700
Cash to meet current obligations	590	3,914	590	1,567	451
Working Capital	3,356		3,356
Current assets	3,883		3,883	5,108
Current liabilities	527		527	574
Net loss	-1,529	-422
Net cash used in operating activities	-977	-1,196
Accumulated deficit	-19,896		-19,896	-18,367
Net cash provided by financing activities		$4,663	$15,345

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Summary of concentrations of net accounts receivable with customers
Allowance for doubtful accounts	($390)	($390)
Accounts receivable, net	682	982
Cenegenics [Member]
Summary of concentrations of net accounts receivable with customers
Accounts receivable, gross	$1,072	$1,372

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Intangibles with finite lives:
Intellectual property	$2,101	$2,101
Less: accumulated amortization	-207	-155
Total intangibles with finite lives:	1,894	1,946
Intangibles with indefinite lives:
Total intangibles with indefinite lives:	44	44
Total intangible assets, net	1,938	1,990
Intellectual Property [Member]
Intangibles with indefinite lives:
Total intangibles with indefinite lives:
Patents [Member]
Intangibles with indefinite lives:
Total intangibles with indefinite lives:	$44	$44

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details Textual) (USD $)	1 Months Ended	3 Months Ended			12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jul. 31, 2014	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2011
Summary of Significant Accounting Policies (Textual)
Cash		$590	$1,567		$1,567
Cash, uninsured amount		309	1,292		1,292
Cash equivalents
Bad debt expense		0			0
Estimated useful lives of fixed assets		3 to 7 years.
Noncash impairment charges of intangible assets
Intellectual property asset, fair value						2,000
Intangible asset acquired	101
Discount Rate	10.00%
Amortization expense for intangible assets year one		210
Amortization expense for intangible assets, year two		210
Amortization expense for intangible assets, year three		210
Amortization expense for intangible assets, year four		210
Amortization expense for intangible assets, year five		210
Shipping and handling costs		0		1
Anti-dilutive excluded from diluted net loss per share computation		1,447,115	777,542
Research and Development Expense		189		434
Amortization expense for intangible assets		$158
Patents [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life of intangible assets		20 years
Intellectual Property [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life of intangible assets		10 years
Unvested restricted stock awards [Member]
Summary of Significant Accounting Policies (Textual)
Anti-dilutive excluded from diluted net loss per share computation		18,050	22,200
Options Held [Member]
Summary of Significant Accounting Policies (Textual)
Anti-dilutive excluded from diluted net loss per share computation		470,880	281,820
Warrant [Member]
Summary of Significant Accounting Policies (Textual)
Anti-dilutive excluded from diluted net loss per share computation		958,185	473,522

Inventories_Net_Details

Inventories, Net (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Summary of Inventory
Raw materials	$1,638	$1,638
Work in process	2	2
Finished goods	435	443
Inventories, gross	2,075	2,083
Less: inventory reserves	-265	-269
Inventories, net	$1,810	$1,814

Fixed_Assets_Details

Fixed Assets (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment, Gross
Total fixed assets	$408	$401
Less: accumulated depreciation and amortization	-100	-88
Net book value of fixed assets	308	313
Furniture, fixtures and equipment [Member]
Property, Plant and Equipment, Gross
Total fixed assets	134	134
Computers and software [Member]
Property, Plant and Equipment, Gross
Total fixed assets	28	21
Leasehold improvements [Member]
Property, Plant and Equipment, Gross
Total fixed assets	239	239
Other [Member]
Property, Plant and Equipment, Gross
Total fixed assets	$7	$7

Fixed_Assets_Details_Textuals

Fixed Assets (Details Textuals) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Fixed Assets (Textual)
Depreciation	$12	$12

Debt_Details

Debt (Details) (USD $)	3 Months Ended	12 Months Ended	0 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Apr. 01, 2015
Debt (Textual)
Debt aggregate principal amount	$500
Debt disbursement at a per annum interest rate	prime rate plus 1.25
Total outstanding balance
Subsequent Event [Member]
Debt (Textual)
Borrowings of revolving note			500
Remaining available balance to borrowings			$0

Prepaid_Expenses_Other_Current2

Prepaid Expenses, Other Current Assets and Accrued Expenses (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Summary of prepaid expenses and other current assets
Prepaid insurance	$84	$46
Prepaid research and development	6	15
Prepaid consulting	8	8
Prepaid inventory purchases	682	664
Other	21	12
Total prepaid expenses and other current assets	$801	$745

Prepaid_Expenses_Other_Current3

Prepaid Expenses, Other Current Assets and Accrued Expenses (Details 1) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Summary of accrued liabilities
Advertising and promotional expense payable	$171	$171
Audit fees payable	68	25
Deferred rent	56	30
Research & development	20	49
Accrued salaries & bonuses		92
Consulting fees payable	21	96
Other accrued expenses	14	32
Total accrued expenses	$350	$495

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Class of Stock [Line Items]
Beginning Balance	$6,736
Forfeiture of prior shares issued for services
Stock-based compensation expense	287	303
Net loss	-1,529	-422
Ending Balance	5,494
Common Stock [Member]
Class of Stock [Line Items]
Beginning Balance	3
Beginning Balance, shares	3,103,300
Forfeiture of prior shares issued for services
Forfeiture of prior shares issued for services, Shares	-1,000
Stock-based compensation expense
Net loss
Ending Balance	3
Ending Balance, shares	3,102,300
Additional Paid-in Capital [Member]
Class of Stock [Line Items]
Beginning Balance	25,100
Forfeiture of prior shares issued for services
Stock-based compensation expense	287
Net loss
Ending Balance	25,387
Retained Earnings [Member]
Class of Stock [Line Items]
Beginning Balance	-18,367
Forfeiture of prior shares issued for services
Stock-based compensation expense
Net loss	-1,529
Ending Balance	($19,896)

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015		Dec. 31, 2014
Class of Stock [Line Items]
Shares	3,102,300		3,103,300
Gross Proceeds	$15,902
February 25, 2011 [Member]
Class of Stock [Line Items]
Shares	95,334
Gross Proceeds	1,430
May 31, 2011 [Member]
Class of Stock [Line Items]
Shares	28,200
Gross Proceeds	423
June 27, 2011 [Member]
Class of Stock [Line Items]
Shares	37,500
Gross Proceeds	563
July 12, 2011 [Member]
Class of Stock [Line Items]
Shares	1,667
Gross Proceeds	25
December 2, 2011 [Member]
Class of Stock [Line Items]
Shares	4,000
Gross Proceeds	40
February 10, 2012 [Member]
Class of Stock [Line Items]
Shares	65,000
Gross Proceeds	325
February 14, 2012 [Member]
Class of Stock [Line Items]
Shares	80,000
Gross Proceeds	400
March 7, 2012 [Member]
Class of Stock [Line Items]
Shares	20,000
Gross Proceeds	100
March 15, 2012 [Member]
Class of Stock [Line Items]
Shares	35,000
Gross Proceeds	175
March 22, 2012 [Member]
Class of Stock [Line Items]
Shares	5,000
Gross Proceeds	25
April 9, 2012 [Member]
Class of Stock [Line Items]
Shares	20,000
Gross Proceeds	100
April 24, 2012 [Member]
Class of Stock [Line Items]
Shares	4,000	[1]
Gross Proceeds		[1]
June 28, 2012 [Member]
Class of Stock [Line Items]
Shares	48,000
Gross Proceeds	600
July 6, 2012 [Member]
Class of Stock [Line Items]
Shares	411,600
Gross Proceeds	5,145
January 27, 2014 [Member]
Class of Stock [Line Items]
Shares	631,346
Gross Proceeds	4,735
November 19, 2014 [Member]
Class of Stock [Line Items]
Shares	193,865
Gross Proceeds	$1,816
[1]	Shares issued under price protection agreement

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Stockholders' Equity [Abstract]
Proceeds from private placement of common stock	$15,902

Warrants_Details

Warrants (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Summary of warrants issued to private placement stockholders and consultants
Shares Underlying Warrants Outstanding at March 31, 2015	470,880
Shares Underlying Warrants Exercisable at March 31, 2015	260,570
Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Number of Shares Underlying Warrants Granted	958,185
Shares Underlying Warrants Exchanged, Exercised or Expired
Shares Underlying Warrants Outstanding at March 31, 2015	958,185
Shares Underlying Warrants Exercisable at March 31, 2015	667,387
Series A Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	27-Jan-14	[1]
Number of Shares Underlying Warrants Granted	315,676	[1]
Shares Underlying Warrants Exchanged, Exercised or Expired		[1]
Shares Underlying Warrants Outstanding at March 31, 2015	315,676	[1]
Shares Underlying Warrants Exercisable at March 31, 2015	315,676	[1]
Exercise Price	15	[1]
Expiration Term in Years	1 year 9 months 29 days	[1]
Series B Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	27-Jan-14	[1]
Number of Shares Underlying Warrants Granted	157,846	[1]
Shares Underlying Warrants Exchanged, Exercised or Expired		[1]
Shares Underlying Warrants Outstanding at March 31, 2015	157,846	[1]
Shares Underlying Warrants Exercisable at March 31, 2015	157,846	[1]
Exercise Price	45	[1]
Expiration Term in Years	3 years 9 months 26 days	[1]
Series C Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	19-Nov-14	[2]
Number of Shares Underlying Warrants Granted	145,399	[2]
Shares Underlying Warrants Exchanged, Exercised or Expired		[2]
Shares Underlying Warrants Outstanding at March 31, 2015	145,399	[2]
Shares Underlying Warrants Exercisable at March 31, 2015		[2]
Exercise Price	12	[2]
Expiration Term in Years	5 years 1 month 17 days	[2]
Series D Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	19-Nov-14	[2]
Number of Shares Underlying Warrants Granted	193,865	[2]
Shares Underlying Warrants Exchanged, Exercised or Expired		[2]
Shares Underlying Warrants Outstanding at March 31, 2015	193,865	[2]
Shares Underlying Warrants Exercisable at March 31, 2015	193,865	[2]
Exercise Price	9.37	[2]
Expiration Term in Years	1 month 17 days	[2]
Series E Warrants [Member]
Summary of warrants issued to private placement stockholders and consultants
Grant Date	19-Nov-14	[2]
Number of Shares Underlying Warrants Granted	145,399	[2]
Shares Underlying Warrants Exchanged, Exercised or Expired		[2]
Shares Underlying Warrants Outstanding at March 31, 2015	145,399	[2]
Shares Underlying Warrants Exercisable at March 31, 2015		[2]
Exercise Price	15	[2]
Expiration Term in Years	7 years 1 month 17 days	[2]
[1]	Issued in connection with the January 27, 2014 private placement transaction.
[2]	Issued in connection with the November 19, 2014 registered-direct public offering.

Warrants_Details_1

Warrants (Details 1) (Warrants [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Assumption used to value warrants using Black-Scholes pricing model
Number of Shares Underlying Warrants Granted	958,185
Expected Term	1 year
Expected volatility	95.00%
Dividend Yield	0.00%
Risk Free Rate	1.47%
Series A January 27, 2014
Assumption used to value warrants using Black-Scholes pricing model
Number of Shares Underlying Warrants Granted	315,676
Stock Price on Measurement Date	7
Exercise Price	15
Expected Term	3 years
Expected volatility	150.00%
Dividend Yield	0.00%
Risk Free Rate	0.76%
Series B January 27, 2014
Assumption used to value warrants using Black-Scholes pricing model
Number of Shares Underlying Warrants Granted	157,846
Stock Price on Measurement Date	7
Exercise Price	45
Expected Term	5 years
Expected volatility	150.00%
Dividend Yield	0.00%
Risk Free Rate	1.61%
Series C November 19, 2014
Assumption used to value warrants using Black-Scholes pricing model
Number of Shares Underlying Warrants Granted	145,399
Stock Price on Measurement Date	9.37
Exercise Price	12
Expected Term	5 years 6 months
Expected volatility	94.60%
Dividend Yield	0.00%
Risk Free Rate	1.64%
Series D November 19, 2014
Assumption used to value warrants using Black-Scholes pricing model
Number of Shares Underlying Warrants Granted	193,865
Stock Price on Measurement Date	9.37
Exercise Price	9.37
Expected Term	6 months
Expected volatility	93.44%
Dividend Yield	0.00%
Risk Free Rate	0.07%
Series E November 19, 2014
Assumption used to value warrants using Black-Scholes pricing model
Number of Shares Underlying Warrants Granted	145,399
Stock Price on Measurement Date	9.37
Exercise Price	15
Expected Term	7 years 6 months
Expected volatility	94.60%
Dividend Yield	0.00%
Risk Free Rate	1.64%

Warrants_Details_Textual

Warrants (Details Textual) (USD $)	0 Months Ended	3 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Nov. 19, 2014	Mar. 31, 2015	Jan. 27, 2014
Warrants (Textual)
Estimated fair value of warrants	$1,049
Public Offering [Member]
Warrants (Textual)
Number of Shares Underlying Warrants Granted	484,663
Common stock price, per share	$14.06
Additional share issued	193,865
Warrant [Member]
Warrants (Textual)
Number of Shares Underlying Warrants Granted		958,185
Expected Term		1 year
Warrant [Member] | Series A January 27, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Granted		315,676
Exercise Price		15
Expected Term		3 years
Warrant [Member] | Series B January 27, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Granted		157,846
Exercise Price		45
Expected Term		5 years
Warrant [Member] | Series C November 19, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Granted		145,399
Exercise Price		12
Expected Term		5 years 6 months
Estimated fair value of warrants		969
Warrants holders entitle to purchase shares of common stock period, Description		66-months
Warrant [Member] | Series D November 19, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Granted		193,865
Exercise Price		9.37
Expected Term		6 months
Estimated fair value of warrants		470
Warrants holders entitle to purchase shares of common stock period, Description		6-months
Warrant [Member] | Series E November 19, 2014
Warrants (Textual)
Number of Shares Underlying Warrants Granted		145,399
Exercise Price		15
Expected Term		7 years 6 months
Estimated fair value of warrants		1,048
Warrants holders entitle to purchase shares of common stock period, Description		90-months
Warrant [Member] | Public Offering [Member]
Warrants (Textual)
Number of Shares Underlying Warrants Granted			473,522
Estimated fair value of warrants			$2,486

Stock_Compensation_Details

Stock Compensation (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Balance, Shares Underlying Options/Warrants	470,880
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning Balance, Shares Underlying Options/Warrants	367,080
Warrants/Options granted, Shares Underlying Warrants/Options	108,000
Options/Warrants exercised, Share Underlying Options/Warrants
Options/Warrants forfeited/expired, Shares Underlying Options/Warrants	-4,200
Balance, Shares Underlying Options/Warrants	470,880	367,080
Beginning Balance, Weighted Average Exercise Price	$14.68
Warrants/Options granted, Weighted Average Exercise Price	$12.50
Warrants/Options exercised, Weighted Average Exercise Price
Warrants/Options cancelled/forfeited, Weighted Average Exercise Price	($10)
Balance, Weighted Average Exercise Price	$14.22	$14.68
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	8 years 7 months 10 days	8 years 6 months

Stock_Compensation_Details_1

Stock Compensation (Details 1) (Stock Options [Member])	3 Months Ended
	Mar. 31, 2015
Assumption used to value options using Black-scholes model
Expected volatility	98.00%
Expected dividend yield	0.00%
Maximum [Member]
Assumption used to value options using Black-scholes model
Risk-free interest rate	1.69%
Expected term (years)	6 years 3 months 18 days
Minimum [Member]
Assumption used to value options using Black-scholes model
Risk-free interest rate	1.39%
Expected term (years)	5 years 9 months 18 days

Stock_Compensation_Details_2

Stock Compensation (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Summary of option outstanding and exercisable
Options outstanding	470,880
Options Exercisable	260,570
$ 7.00 [Member]
Summary of option outstanding and exercisable
Options outstanding	5,000	5,000
Options Granted, Weighted Average Remaining Contractual Life	7 years 1 month 21 days
Options Exercisable	5,000
Options Exercisable, Weighted Average Remaining Contractual Life	7 years 1 month 21 days
Options Granted, Range of Exercise Price	$7
Options exercisable, Range of Exercise Price	$7
$ 8.60 [Member]
Summary of option outstanding and exercisable
Options outstanding	30,500	30,500
Options Granted, Weighted Average Remaining Contractual Life	8 years 11 months 12 days
Options Exercisable	15,250
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 11 months 12 days
Options Granted, Range of Exercise Price	$8.60
Options exercisable, Range of Exercise Price	$8.60
$ 10.00 [Member]
Summary of option outstanding and exercisable
Options outstanding	5,120	12,120
Options Granted, Weighted Average Remaining Contractual Life	7 years 10 months 10 days
Options Exercisable	5,120
Options Exercisable, Weighted Average Remaining Contractual Life	7 years 10 months 10 days
Options Granted, Range of Exercise Price	$10
Options exercisable, Range of Exercise Price	$10
$ 11.00 [Member]
Summary of option outstanding and exercisable
Options outstanding	3,000	3,000
Options Granted, Weighted Average Remaining Contractual Life	7 years 9 months 11 days
Options Exercisable	3,000
Options Exercisable, Weighted Average Remaining Contractual Life	7 years 9 months 11 days
Options Granted, Range of Exercise Price	$11
Options exercisable, Range of Exercise Price	$11
$ 12.10 [Member]
Summary of option outstanding and exercisable
Options outstanding	30,500	30,500
Options Granted, Weighted Average Remaining Contractual Life	9 years 1 month 10 days
Options Exercisable	7,625
Options Exercisable, Weighted Average Remaining Contractual Life	9 years 1 month 10 days
Options Granted, Range of Exercise Price	$12.10
Options exercisable, Range of Exercise Price	$12.10
$ 12.50 [Member]
Summary of option outstanding and exercisable
Options outstanding	214,200	106,200
Options Granted, Weighted Average Remaining Contractual Life	9 years 4 days
Options Exercisable	94,425
Options Exercisable, Weighted Average Remaining Contractual Life	8 years 3 months 4 days
Options Granted, Range of Exercise Price	$12.50
Options exercisable, Range of Exercise Price	$12.50
$ 12.55 [Member]
Summary of option outstanding and exercisable
Options outstanding	20,000	20,000
Options Granted, Weighted Average Remaining Contractual Life	9 years 1 month 21 days
Options Exercisable
Options Granted, Range of Exercise Price	$12.55
Options exercisable, Range of Exercise Price	$12.55
$ 13.00 [Member]
Summary of option outstanding and exercisable
Options outstanding	14,600	14,600
Options Granted, Weighted Average Remaining Contractual Life	9 years 3 months 11 days
Options Exercisable	3,650
Options Exercisable, Weighted Average Remaining Contractual Life	9 years 3 months 11 days
Options Granted, Range of Exercise Price	$13
Options exercisable, Range of Exercise Price	$13
$ 13.45 [Member]
Summary of option outstanding and exercisable
Options outstanding	2,000	2,000
Options Granted, Weighted Average Remaining Contractual Life	9 years 2 months 23 days
Options Exercisable
Options Granted, Range of Exercise Price	$13.45
Options exercisable, Range of Exercise Price	$13.45
$ 13.50 [Member]
Summary of option outstanding and exercisable
Options outstanding	14,960	14,960
Options Granted, Weighted Average Remaining Contractual Life	9 years 2 months 27 days
Options Exercisable
Options Granted, Range of Exercise Price	$13.50
Options exercisable, Range of Exercise Price	$13.50
$ 13.75 [Member]
Summary of option outstanding and exercisable
Options outstanding	6,000	6,000
Options Granted, Weighted Average Remaining Contractual Life	9 years 5 months 5 days
Options Exercisable	1,500
Options Exercisable, Weighted Average Remaining Contractual Life	9 years 5 months 5 days
Options Granted, Range of Exercise Price	$13.75
Options exercisable, Range of Exercise Price	$13.75
$ 17.50 [Member]
Summary of option outstanding and exercisable
Options outstanding	100,000	100,000
Options Granted, Weighted Average Remaining Contractual Life	7 years 10 months 10 days
Options Exercisable	100,000
Options Exercisable, Weighted Average Remaining Contractual Life	7 years 10 months 10 days
Options Granted, Range of Exercise Price	$17.50
Options exercisable, Range of Exercise Price	$17.50
$ 22.50 [Member]
Summary of option outstanding and exercisable
Options outstanding	5,000	5,000
Options Granted, Weighted Average Remaining Contractual Life	6 years 4 months 13 days
Options Exercisable	5,000
Options Exercisable, Weighted Average Remaining Contractual Life	6 years 4 months 13 days
Options Granted, Range of Exercise Price	$22.50
Options exercisable, Range of Exercise Price	$22.50
$ 32.00 [Member]
Summary of option outstanding and exercisable
Options outstanding	15,000	15,000
Options Granted, Weighted Average Remaining Contractual Life	6 years 3 months 11 days
Options Exercisable	15,000
Options Exercisable, Weighted Average Remaining Contractual Life	6 years 3 months 11 days
Options Granted, Range of Exercise Price	$32
Options exercisable, Range of Exercise Price	$32
$ 34.50 [Member]
Summary of option outstanding and exercisable
Options outstanding	5,000	5,000
Options Granted, Weighted Average Remaining Contractual Life	6 years 3 months 22 days
Options Exercisable	5,000
Options Exercisable, Weighted Average Remaining Contractual Life	6 years 3 months 22 days
Options Granted, Range of Exercise Price	$34.50
Options exercisable, Range of Exercise Price	$34.50

Stock_Compensation_Details_3

Stock Compensation (Details 3) (Restricted Stock Issuances [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Restricted Stock Issuances [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Shares	22,200
Shares granted, Shares
Shares vested, Shares	-3,150
Shares forfeited, Shares	-1,000
Balance, Shares	18,050
Beginning Balance, Weighted Average Grant Date Share Price	$14.95
Shares granted, Weighted Average Grant Date Share Price
Shares vested, Weighted Average Grant Date Share Price	$7.75
Shares forfeited, Weighted Average Grant Date Share Price	$7.50
Balance, Weighted Average Grant Date Share Price	$16.62

Stock_Compensation_Details_4

Stock Compensation (Details 4) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$287	$303
Cost of sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	25	19
Selling, general and administrative expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$262	$284

Stock_Compensation_Details_Tex

Stock Compensation (Details Textual) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Options outstanding	470,880
Weighted average grant date fair value	$5.22
Stock-based compensation expense	$287	$303
Warrants [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Options outstanding	958,185
Weighted average exercise price, per share			$18.35
2012 Equity Incentive Plan [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Number of shares authorized for issuance	550,000
Common stock reserved for issuance	109,120
Options outstanding	30,000		30,000
Number of shares non-vested			220,543
Vested options, Weighted average remaining contractual life	8 years
Vested options Weighted average exercise price, per share	$15.76
Weighted average exercise price, per share			$0.23
Weighted average unvested restricted stock remaining term	1 year 8 months 1 day
Aggregate unrecognized compensation expense of options	1,470
2012 Equity Incentive Plan [Member] | Minimum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Vesting terms range	1 month 6 days
2012 Equity Incentive Plan [Member] | Maximum [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Vesting terms range	3 years 9 months 18 days
Stock Options [Member]
Warrants, Options, Equity Incentive Plan and Stock Issuances (Textual)
Options outstanding	470,880		367,080
Aggregate intrinsic value of outstanding options	0
Aggregate intrinsic value of exercisable options	$0
Market price of common stock	$4.58
Number of shares non-vested	210,310		200,518
Weighted average exercise price, per share	$14.22		$14.68

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Summary of future minimum lease payments under the non-cancelable operating lease
2015 (remaining nine months)	$134
2016	152
2017	181
2018	187
2019	191
Total	$845

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual)	3 Months Ended	12 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2014
	USD ($)	USD ($)	Supply Agreement [Member]	Supply Agreement [Member]	Supply Agreement [Member]	Supply Agreement [Member]
	sqft		USD ($)	EUR (€)	USD ($)	EUR (€)
Commitments and Contingencies (Textual)
Office space	14,304
Rent expense	$55	$17
Minimum purchase obligations under the agreement, 2015			2,137	1,969
Minimum purchase obligations under the agreement, 2016			1,875	1,728
Minimum purchase obligations under the agreement			469	432	262	241
Prepaid expenses and other current assets	801	745	663
Lease expiration date	31-Dec-19
Percentage of matching contribution of employer	100.00%
Description of matching contribution of defined contribution plan	The Company's matching contribution is equal to 100 percent on the first four percent of a participant's compensation which is deferred as an elective deferral.
Matching contribution, amount	$14	$0
Expiration date of agreement			31-Dec-16	31-Dec-16
Renewal term of agreement	We have two options to renew our lease for an additional three years each.		May be renewed for additional one-year periods unless terminated by either party by giving ninety days notice before the expiration of the current term.	May be renewed for additional one-year periods unless terminated by either party by giving ninety days notice before the expiration of the current term.
Term of lease	5 years